MDNA 55

Drug Profile

MDNA 55

Alternative Names: cpIL4-PE; IL-4 Superkines™; IL4-EC; IL4-PE; Interleukin-4 Empowered Cytokine™; Interleukin-4 PE38KDEL cytotoxin; Interleukin-4 PE38KDEL immunotoxin; Interleukin-4 Pseudomonas toxin; Interleukin-4(38-37)-PE38KDEL; Interleukin-4-Pseudomonas exotoxin; Interleukin-4-Pseudomonas exotoxin fusion protein; INxin; MDNA 55; NBI-3001; PRX321

Latest Information Update: 30 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator National Institutes of Health (USA); Neurocrine Biosciences
  • Developer Medicenna Therapeutics; Sophiris Bio
  • Class Antineoplastics; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Brain metastases
  • Preclinical Brain cancer; Glioma
  • Research Bladder cancer
  • Discontinued Solid tumours

Most Recent Events

  • 09 Aug 2017 Medicenna plans a phase II trial for Brain cancer (Metastatic disease) in the second half of 2017
  • 25 May 2017 Preclinical trials in Brain cancer in USA (IV)
  • 27 Apr 2017 Medicenna Therapeutics has issued and pending patents for Superkine and Empowered Cytokine platforms in USA, Canada, European Union and Asia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top